ABSTRACT
OBJECTIVE@#To explore the mechanisms underlying the proliferative inhibition of Chinese herbal medicine Kang-Ai injection (KAI) in gastric cancer cells.@*METHODS@#Gastric cancer cell lines MGC803 and BGC823 were treated by 0, 0.3%, 1%, 3% and 10% KAI for 24, 48 and 72 h, respectively. The cell proliferation was evaluated by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay. The apoptosis and cell cycle were evaluated by flow cytometry. Interleukin (IL)-6 mRNA and protein expression levels were detected by quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-linked immune sorbent assay (ELISA), respectively. The protein expression levels of cyclin A, cyclin E, cyclin B1, cyclin D1, p21, retinoblastoma (RB), protein kinase B (AKT), extracellular regulated protein kinases (ERK), signal transducer and activator of transcription (STAT) 1 and STAT3 were detected by Western blot.@*RESULTS@#KAI inhibited the proliferation of MGC803 and BGC823 gastric cancer cells in dose- and time-dependent manner. After treated with KAI for 48 h, the proportion of G1 phase was increased, expression level of cyclin D1 and phosphorylation-RB were down-regulated, whereas the expression of p21 was up-regulated (all P<0.01). Furthermore, 48-h treatment with KAI decreased the phosphorylation level of STAT3, inhibited the mRNA and protein expressions of IL-6 (all P<0.01). IL-6 at dose of 10 ng/mL significantly attenuated the proliferative effect of both 3% and 10% KAI, and recovered KAI-inhibited STAT3 phosphorylation and cyclin D1 expression level (all P<0.01).@*CONCLUSION@#KAI exerted an anti-proliferative function by inhibiting IL-6/STAT3 signaling pathway followed by the induction of G1 phase arrest in gastric cancer cells.
Subject(s)
Humans , Apoptosis , Cell Line, Tumor , Cell Proliferation , Cyclin D1/pharmacology , Interleukin-6/metabolism , RNA, Messenger/metabolism , STAT3 Transcription Factor/metabolism , Stomach Neoplasms/geneticsABSTRACT
Objective To observe the effectiveness and safety of Kang′ai injection combined with docetaxel or gemcitabine chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer(NSCLC). Methods A multi-center,randomized and parallel control study was carried out in 150 elderly patients with ad-vanced NSCLC treated in 3 hospitals during the period from June 2013 to August 2014.The patients were randomly divided into platinum-based group(platinum-based doublet chemotherapy)and Kang′ai group(Kang′ai injection combined with single agent chemotherapy). The clinical efficacy,quality of life and adverse reactions were ob-served and compared between the two groups. Results There was no significant difference in the disease control rate between the two groups group(79.66% vs 81.82%)(χ2=0.101,P=0.751)while the effective rate of Kang′ai group was significantly higher than that of platinum-based group(30.51% vs 14.29%)(χ2=5.240,P=0.022). The effective rate of clinical symptom relief in Kang′ai group after treatment was significantly higher than that in platinum-based group(69.49% vs 48.05%)(χ2=6.278,P=0.012),and the increase rate of PS score in Kang′ai group after the treatment was also significantly higher than that in platinum-based group(18.64% vs 3.90%)(χ2=7.868,P=0.005).There was no significant difference in quality of life between two groups(P>0.05).The quali-ty of life score of Kang′ai group was significantly higher than that of platinum-based group at the second course of treatment(P<0.05).The incidence of adverse reactions in Kang′ai group was significantly lower than that in the platinum-based group(47.46% vs 71.42%)(χ2= 8.070,P < 0.05). Conclusion Kang′ai injection combined with single agent chemotherapy can effectively relieve clinical symptoms and reduce the tumor size in elderly patients with advanced NSCLC,with high safety.
ABSTRACT
OBJECTIVE:To investigate clinical efficacy and safety of Kang'ai injection adjuvant chemotherapy for advanced lung cancer. METHODS:A total of 146 patients with advanced lung cancer during May 2013-Apr. 2014 were divided into observa-tion group and control group according to odd-even admission number,with 73 cases in each group. Control group was given GP (gemcitabine+cisplatin)chemotherapy. Observation group was additionally given Kang'ai injection 60 mL added into normal saline 250 mL,qd,ivgtt,for consecutive 14 d each chemotherapy cycle,on the basis of control group. Both groups were given tropise-tron 5 mg for preventing gastrointestinal reaction during chemotherapy. A treatment course lasted for 3 weeks,and both groups were treated for 3 courses. Clinical efficacies of 2 groups were compared;the levels of serum inflammatory factors (hs-CRP, TNF-α,IFN-γ,IL-10),immune function indexes(CD3+,CD4+,CD8+,CD4+/CD8+)and tumor markers(SCC-Ag,CEA,CA50, CA72-4) were compared before and after treatment. The occurrence of ADR were recorded in 2 groups. RESULTS:The response rate and disease control rate of observation group were 39.73％ and 84.93％,which were significantly higher than 23.29％ and 71.23％ of control group,with statistical significance(P<0.05). Before treatment,there was no statistical significance in the lev-els of serum inflammatory factors,immune function indexes or tumor markers between 2 groups (P>0.05). After treatment,the levels of hs-CRP,TNF-αand IFN-γin 2 groups were significantly lower than before treatment,while the level of IL-10 was signifi-cantly higher than before treatment;above indexes of observation group were significantly better than control group,with statistical significance(P<0.05). The levels of CD4+ and CD4+/CD8+ in control group were decreased significantly and lower than observa-tion group,with statistical significance(P<0.05). Serum levels of SCC-Ag,CEA,CA50 and CA72-4 in 2 groups were decreased significantly,and observation group was significantly lower than control group,with statistical significance(P<0.05). The inci-dence of thrombocytopenia,neutropenia,abnormal liver function,nausea and vomiting,anemia in observation group were signifi-cantly lower than control group,with statistical significance(P<0.05). CONCLUSIONS:Kang'ai injection adjuvant chemothera-py can effectively relieve inflammation symptoms of patients with advanced lung cancer,reduce toxic reactions,enhance immune function, and improve short-term therapeutic efficacy with good safety.
ABSTRACT
Objective To explore the effect of Kang′ai injection in the chemotherapy treatment of gastroin-testinal cancer.Methods 97 patients with gastrointestinal cancer were divided into the control group(49 cases) and the observation group(48 cases) in accordance with the random number table.The control group received common chemotherapy treatment,while the observation group was plused Kang'ai injection based on the same treatment.The near time clinical efficacy and survival rate in three years between the two groups were compared.Results The near time total effective rate of the observation group was 89.58%, which was significantly higher than 71.43% of the control group(χ2 =19.278,P<0.05).The improvement rate of quality of life in the observation group was 68.75%, which was significantly higher than 30.61% of the control group(χ2 =10.876,P<0.05).The reduction rate of quality of life in the observation group was 10.42%,which was significantly lower than 34.69%of the control group (χ2 =12.674,P<0.05).About adverse reactions rate above Ⅲ°,the gastrointestinal in the observation group was 6.25%,which was significantly lower than 22.45%of the control group(χ2 =14.523,P<0.05).The blood adverse reactions rate in the observation group was 0.00%,which was significantly lower than 12.24% of the control group (χ2 =17.795,P <0.05).The survival rates of 1,2,3 years in the observation group were 91.67%,75.00%, 60.42%,respectively,which were significantly higher than 77.55%,59.18%,34.69% in the control group(χ2 =9.547,13.697,15.862,all P<0.05).Conclusion Kang′ai injection can improve the tolerance of gastrointestinal cancer to chemotherapy treatment,reduce adverse reactions rate,improve quality of life and prolong survival.
ABSTRACT
Objective:To analyze the value of Kang'ai injection on gastric cancer patients’ chemotherapy.Methods: Chosen gastric cancer patients with chemotherapy between December 2012 to December 2013 in our hospital as study subject, randomly divided into control group received conventional chemotherapy and observation groups received Kang'ai injection combine with chemotherapy, compared term effect after chemotherapy, immune function and quality of life scores.Results: 1)Observation group patients’ complete remission and partial remission after chemotherapy were significantly higher than control group patients(x2=2.471,x2=2.748;P<0.05); 2)Observation group patients’ IL-6, TNF-α, CD3+, CD4+ value was significantly higher than control group after receiving chemotherapy, CD8+ value was significantly lower than control group patients(t=2.627,t=2.462,t=2.748,t=2.846,t=2.735;P<0.05); 3)two groups of patients’ life quality scores before chemotherapy was no significant,after chemotherapy observation group patients’ life quality scores were significantly higher than control group patients(t=2.637,t=2.647,t=2.983;P<0.05).Conclusion: Kang'ai injection can significantly improve the effectiveness of chemotherapy in patients with gastric cancer,and optimize immune function, while improving the quality of life after chemotherapy.
ABSTRACT
Objective To investigate the effect of Kang' ai injection and Shenqifuzheng injection on liver function of patients with advanced primary liver cancer after being performed transcatheter arterial chemomembolization (TACE).Methods 120 patients with advanced primary liver cancer were randomly divided into three groups:a control group,a Kang'ai injection group,and a Shenqifuzheng injection group,with 40 patients in each group.All three groups were treated with TACE,and after TACE the control group was treated with anti-infection,inhibiting-acid,protecting-liver function and Shuganning tablets,20 ml/day.On this basis,the Kang'ai injection group was additionally injected with Kang'ai injection,40ml/day,and Shenqifuzheng injection group was additionally injected with Shenqifuzheng injection,250ml/day.All three groups were treated for 15 days.Liver function was tested and compared at the 3rd day,the 7th day and 14th day after TACE in all three groups.Results At the 14th day after TACE,ALT,AST,TBiL,and TBA of the Kang' ai group and Senqifuzheng group [(40.35 ± 10.10) μmol/L、(37.52 ± 10.57) μmol/L、(40.13 ± 8.36) μmol/L、(45.19 ± 19.65) μmol/L in Senqifuzheng group; (40.11 ±7.31) μmol/L,(34.99±9.38) μmol/L,(32.15±6.58) μmol/L,(40.75 ± 6.79) μmol/L in Kang'ai group] were greatly improved than the control group [(61.28 ± 13.38) μmol/L,(57.53 ± 13.36) μmol/L,(68.69± 7.25) μmol/L,(67.75 ± 17.88) μmol/L],with statistical significance (P＜ 0.01).Conclusion Kang'ai injiection and Shenqifuzhcng injection both can reduce liver function damage caused by TACE,thus they can be used together with TACE for treating advanced primary liver cancer.